Heidi Elliot

559 citations
14 papers · 206 · h-index 7

Impact in

Papers in

  • Genetics 10
    • Hemoglobinopathies and Related Disorders 10
    • Neurogenetic and Muscular Disorders Research 2
    • Virus-based gene therapy research 2
  • Pediatrics, Perinatology and Child Health 6
    • Prenatal Screening and Diagnostics 5
    • Neonatal Health and Biochemistry 1
Co-authors
H. Y. Elder (1 shared paper)I. Fogelman (1 shared paper)G. H. Beastall (1 shared paper)B.F. Boyce (1 shared paper)B. J. R. Junor (1 shared paper)I.T. Boyle (1 shared paper)G. S. Fell (1 shared paper)Janet L. Kwiatkowski (12 shared papers)
Journals
Blood (4 papers)Transplantation and Cellular Therapy (2 papers)HemaSphere (2 papers)Biology of Blood and Marrow Transplantation (2 papers)The Lancet (2 papers)
Partner nations
United StatesUnited KingdomItaly

In The Last Decade

Heidi Elliot

14 papers receiving 190 citations

Peers

Heidi Elliot
Comparison fields: 5 of 43
  • Genetics 59
  • Complementary and Manual Therapy 8
  • Nutrition and Dietetics 58
  • Nephrology 19
  • Health, Toxicology and Mutagenesis 38
Replace Priyanka Mehta with:
Priyanka Mehta United Kingdom
Fatemeh Eini Iran
M. Filioli Uranio Italy
João Felipe Bezerra Brazil
Danni Zhou China
Shaoxin Ye China
Fereshteh Aliakbari Iran
Betty Lind United States
Julie MacFarlane Canada
Heidi Elliot relative to Priyanka Mehta United Kingdom Priyanka Mehta's profile →
Citations per field
00.5×2×4×5.4×
Priyanka Mehta · 1×
Citations per year

Countries citing papers authored by Heidi Elliot

Since Specialization
Citations

This map shows the geographic impact of Heidi Elliot's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Heidi Elliot with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Heidi Elliot more than expected).

Fields of papers citing papers by Heidi Elliot

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Heidi Elliot. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Heidi Elliot. The network helps show where Heidi Elliot may publish in the future.

Co-authors

The 25 scholars most cited alongside Heidi Elliot, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Heidi Elliot Line = papers co-authored together Heidi Elliot links everyone, so they are left out of the graph.

All Works

14 of 14 papers shown
#Work
1
HYPERCALCAEMIC OSTEOMALACIA DUE TO ALUMINIUM TOXICITY
The Lancet ·B.F. Boyce, H. Y. Elder, Heidi Elliot, I. Fogelman, G. S. Fell, B. J. R. Junor, G. H. Beastall, I.T. Boyle
1982121
2
Northstar-3: Interim Results from a Phase 3 Study Evaluating Lentiglobin Gene Therapy in Patients with Transfusion-Dependent β-Thalassemia and Either a β0 or IVS-I-110 Mutation at Both Alleles of the HBB Gene
Blood ·Ashutosh Lal, Franco Locatelli, Janet L. Kwiatkowski, Andreas E. Kulozik, Evangelia Yannaki, John B. Porter, Isabelle Thuret, Martin G. Sauer, Heidi Elliot, Ying Chen, Richard A. Colvin, Alexis A. Thompson
201921
3
Betibeglogene autotemcel gene therapy in patients with transfusion-dependent, severe genotype β-thalassaemia (HGB-212): a non-randomised, multicentre, single-arm, open-label, single-dose, phase 3 trial
The Lancet ·Janet L. Kwiatkowski, Mark C. Walters, Suradej Hongeng, Evangelia Yannaki, Andreas E. Kulozik, Joachim B. Kunz, Martin G. Sauer, Adrian J. Thrasher, Isabelle Thuret, Ashutosh Lal, Tao Ge, Shamshad Ali, Himal L. Thakar, Heidi Elliot, Ankit Lodaya, Ji Hyun Lee, Richard A. Colvin, Franco Locatelli, Alexis A. Thompson
202418
4
Northstar-2: Updated Safety and Efficacy Analysis of Lentiglobin Gene Therapy in Patients with Transfusion-Dependent β-Thalassemia and Non-β0/β0 Genotypes
Blood ·Alexis A. Thompson, Mark C. Walters, Janet L. Kwiatkowski, Suradej Hongeng, John B. Porter, Martin G. Sauer, Adrian J. Thrasher, Isabelle Thuret, Heidi Elliot, Ge Tao, Richard A. Colvin, Franco Locatelli
201912
5
Lentiglobin Gene Therapy for Patients with Transfusion-Dependent β-Thalassemia (TDT): Results from the Phase 3 Northstar-2 and Northstar-3 Studies
Blood ·Franco Locatelli, Mark C. Walters, Janet L. Kwiatkowski, John B. Porter, Martin G. Sauer, Isabelle Thuret, Suradej Hongeng, Andreas E. Kulozik, Ashutosh Lal, Adrian J. Thrasher, Evangelia Yannaki, Heidi Elliot, Ge Tao, Mohammed Asmal, Alexis A. Thompson
201811
6
Efficacy, Safety, and Health-Related Quality of Life (HRQOL) in Patients with Sickle Cell Disease (SCD) Who Have Received Lovotibeglogene Autotemcel (Lovo-cel) Gene Therapy: Up to 60 Months of Follow-up
Blood ·Julie Kanter, Alexis A. Thompson, Janet L. Kwiatkowski, Suhag Parikh, Markus Y. Mapara, Stacey Rifkin-Zenenberg, Banu Aygün, Kimberly A. Kasow, Ashish O. Gupta, Lixin Zhang, Emily Sheldon‐Waniga, Meghan Gallagher, Katiana Gruppioni, Anjulika Chawla, Heidi Elliot, Francis J. Pierciey, Mark C. Walters, John F. Tisdale
20239
7
Interim Results from the Phase 3 Hgb-207 (Northstar-2) and Hgb-212 (Northstar-3) Studies of Betibeglogene Autotemcel Gene Therapy (LentiGlobin) for the Treatment of Transfusion-Dependent β-Thalassemia
Biology of Blood and Marrow Transplantation ·Jennifer Schneiderman, Alexis A. Thompson, Mark C. Walters, Janet L. Kwiatkowski, Andreas E. Kulozik, Martin G. Sauer, John B. Porter, Isabelle Thuret, Suradej Hongeng, Ashutosh Lal, Adrian J. Thrasher, Evangelia Yannaki, Heidi Elliot, Ge Tao, Weijian Liu, Richard A. Colvin, Franco Locatelli
20207
8
S140 RESULTS FROM THE PHASE 3 NORTHSTAR‐3 STUDY EVALUATING LENTIGLOBIN GENE THERAPY IN PATIENTS WITH TRANSFUSION‐DEPENDENT β‐THALASSAEMIA AND A β0 OR IVS‐I‐110 MUTATION AT BOTH ALLELES OF THE HBB GENE
HemaSphere ·Andreas E. Kulozik, Franco Locatelli, Evangelia Yannaki, John B. Porter, Isabelle Thuret, Martin G. Sauer, Ashutosh Lal, Janet L. Kwiatkowski, Heidi Elliot, Ge Tao, Richard A. Colvin, Alexis A. Thompson
20191
9
S1632 SAFETY AND EFFICACY OF LENTIGLOBIN GENE THERAPY IN PATIENTS WITH TRANSFUSION‐DEPENDENT B‐THALASSAEMIA AND NON‐B0/B0 GENOTYPES IN THE PHASE 3 NORTHSTAR‐2 STUDY
HemaSphere ·Franco Locatelli, Alexis A. Thompson, Suradej Hongeng, John B. Porter, Martin G. Sauer, Janet L. Kwiatkowski, Adrian J. Thrasher, Isabelle Thuret, Heidi Elliot, Ge Tao, Richard A. Colvin, Mark C. Walters
20191
10
Lovotibeglogene Autotemcel Gene Therapy for Sickle Cell Disease: 60 Months Follow-up
Julie Kanter, Anjulika Chawla, Alexis A. Thompson, Janet L. Kwiatkowski, Suhag Parikh, Markus Y. Mapara, Stacey Rifkin-Zenenberg, Banu Aygün, Kimberly A. Kasow, Ashish O. Gupta, Lixin Zhang, Emily Sheldon‐Waniga, Meghan Gallagher, Katiana Gruppioni, Heidi Elliot, Francis J. Pierciey, Mark C. Walters, John F. Tisdale
20241
11
Efficacy and Safety in Patients (Pts) with Sickle Cell Disease (SCD) Who Have Received Lovotibeglogene Autotemcel (Lovo-cel) Gene Therapy: Up to 60 Months of Follow-up
Transplantation and Cellular Therapy ·Julie Kanter, Alexis A. Thompson, Janet L. Kwiatkowski, Suhag Parikh, Markus Y. Mapara, Stacey Rifkin-Zenenberg, Banu Aygün, Kimberly A. Kasow, Ashish O. Gupta, Lixin Zhang, Emily Sheldon‐Waniga, Meghan Gallagher, Katiana Gruppioni, Anjulika Chawla, Heidi Elliot, Francis J. Pierciey, Mark C. Walters, John F. Tisdale
20241
12
Efficacy and safety of LentiGlobin gene therapy in patients with transfusion-dependent β-thalassemia and non-β0/β0 genotypes: Updated results from the completed phase 1/2 Northstar and ongoing phase 3 Northstar-2 studies
Cytotherapy ·John E.J. Rasko, Mark C. Walters, Janet L. Kwiatkowski, Suradej Hongeng, John B. Porter, Martin G. Sauer, Adrian J. Thrasher, Isabelle Thuret, Gary J. Schiller, Heidi Elliot, Briana Deary, Y. Chen, Ge Tao, Mohammed Asmal, Franco Locatelli, Alexis A. Thompson
20191
13
Predictors of Biologic Efficacy with Lovotibeglogene Autotemcel (Lovo-cel) Gene Therapy in Patients with Sickle Cell Disease
Transplantation and Cellular Therapy ·Melissa A. Kinney, Ilya Shestopalov, Lauryn Christiansen, Hancheng Jiang, Marianna Foos, Heidi Elliot, Anjulika Chawla, Francis J. Pierciey
20241
14
Lentiglobin Gene Therapy for Transfusion-Dependent β-Thalassemia: Outcomes from the Phase 1/2 Northstar and Phase 3 Northstar-2 Studies
Biology of Blood and Marrow Transplantation ·Usanarat Anurathapan, Franco Locatelli, Janet L. Kwiatkowski, John E.J. Rasko, Gary J. Schiller, John B. Porter, Martin G. Sauer, Adrian J. Thrasher, Christian Chabannon, Heidi Elliot, Briana Deary, Ying Chen, Ge Tao, Mohammed Asmal, Alexis A. Thompson, Mark C. Walters
20191

About Heidi Elliot

Heidi Elliot is a scholar working on Genetics, Pediatrics, Perinatology and Child Health, Molecular Biology, Genetics and Public Health, Environmental and Occupational Health, having authored 14 papers that have together received 206 indexed citations. Recurring topics across this work include Hemoglobinopathies and Related Disorders (10 papers), Prenatal Screening and Diagnostics (5 papers), Neurogenetic and Muscular Disorders Research (2 papers), CRISPR and Genetic Engineering (2 papers), Virus-based gene therapy research (2 papers), Neonatal Health and Biochemistry (1 paper), Acute Lymphoblastic Leukemia research (1 paper) and Trace Elements in Health (1 paper). The work is most often cited by research in Genetics (59 citations), Complementary and Manual Therapy (8 citations), Nutrition and Dietetics (58 citations), Nephrology (19 citations) and Health, Toxicology and Mutagenesis (38 citations). Heidi Elliot has collaborated with scholars based in United States, United Kingdom and Italy. Frequent co-authors include H. Y. Elder, I. Fogelman, G. H. Beastall, B.F. Boyce, B. J. R. Junor, I.T. Boyle, G. S. Fell, Janet L. Kwiatkowski, Alexis A. Thompson and Franco Locatelli. Their work appears in journals such as Blood, Transplantation and Cellular Therapy, HemaSphere, Biology of Blood and Marrow Transplantation and The Lancet.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Priyanka MehtaBreakdown of academic impact, for papers by Fatemeh EiniBreakdown of academic impact, for papers by M. Filioli UranioBreakdown of academic impact, for papers by João Felipe BezerraBreakdown of academic impact, for papers by Danni ZhouBreakdown of academic impact, for papers by Shaoxin YeBreakdown of academic impact, for papers by Fereshteh AliakbariBreakdown of academic impact, for papers by Betty LindBreakdown of academic impact, for papers by Julie MacFarlane